Stay updated on Pembrolizumab for Intermediate Risk NMIBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.

Latest updates to the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page's revision label was updated from v3.6.5 to v3.6.6. This signals a minor maintenance update without changing study details or core content.SummaryDifference0.1%

- Check18 days agoChange DetectedA funding attribution line for 2016 U.S. NIH Grant/Contract was added under Other Study ID Numbers, providing the source of support for the study. This addition adds administrative funding context without altering trial design, endpoints, or eligibility.SummaryDifference0.1%

- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe page footer's revision label was incremented from v3.6.4 to v3.6.5, indicating a small update to the page metadata.SummaryDifference0.1%

- Check47 days agoChange DetectedThe page's revision stamp was updated from v3.6.3 to v3.6.4, replacing the previous revision with a newer version.SummaryDifference0.1%

- Check68 days agoChange DetectedThe page revision label was updated to v3.6.3, and older revision text along with links such as 'Bladder cancer' and 'MedlinePlus Genetics' were removed.SummaryDifference0.2%

- Check76 days agoChange DetectedThe page now displays Revision: v3.6.2, replacing the previous v3.6.0. This reflects a minor version update to the page template.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for Intermediate Risk NMIBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.